US equities
|
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by InnoCare Pharma
< Previous
1
2
3
Next >
Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology
October 16, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China
October 12, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
October 11, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
September 24, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China
September 08, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
August 24, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in China
August 17, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China
August 03, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study
July 27, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Phase II Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Vitiligo
July 16, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Atomic Dermatitis
July 15, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
July 14, 2026
From
InnoCare Pharma
Via
GlobeNewswire
Study Results of Orelabrutinib in Patients with SLE Published in the Journal of Autoimmunity
July 10, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
July 05, 2026
From
InnoCare Pharma
Via
GlobeNewswire
2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL Patients
June 15, 2026
From
InnoCare Pharma
Via
GlobeNewswire
Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR
June 05, 2026
From
InnoCare Pharma
Via
GlobeNewswire
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
June 02, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
May 28, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Approval of Orelabrutinib in Australia
May 27, 2026
From
InnoCare Pharma
Via
GlobeNewswire
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
May 22, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
May 13, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China
May 07, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
May 06, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
April 28, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
April 23, 2026
From
InnoCare Pharma
Via
GlobeNewswire
Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety
April 21, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit
March 25, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China
March 15, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
March 01, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Key Developments of Critical Clinical Studies
February 25, 2026
From
InnoCare Pharma
Via
GlobeNewswire
< Previous
1
2
3
Next >
